SOAN FIRST TITAN CORP

AngioSoma Explains History of Muscles4U.com

AngioSoma Explains History of Muscles4U.com

Houston, TX, Jan. 08, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN). I have worked in the Intensive care unit as well as the cardiac unit, body builder and single mom with one daughter.  When I found my first of two grandchildren was on the way, I decided body building was too intense, so I changed to routine workouts at the gym to stay fit and healthy.

To make my workout more effective and productive, I tried several supplements that were advertised to enhance workouts.  The result was that none of the well-advertised products made any difference and I was disappointed.

After some thought, I came to the well-known solution; “If you want something done right, do it yourself.”  I joined with two people who could make my dream come true.  One is a doctor who had developed the ingredients and formulas for supplements that will really enhance a workout and the other a lawyer to help with the business side.  I settled on four supplements: male and female, each with AM and PM formula that I named, trademarked and patented StemStrength.

The path from there to here was daunting.  I searched and found a manufacturer of the four products, graphics designer for the four labels, ecommerce website designer, credit card processor and means of fulfillment.

After several choosing and then changing the several vendors to make it all come true, I finally came to the present success of Muscles4U by SomaCeuticals, a subsidiary of AngioSoma, a publicly traded corporation.

My name is Alex Blankenship, President and CEO of AngioSoma (OTC:SOAN) and its subsidiary SomaCeuticals.

ABOUT ANGIOSOMA, INC.

AngioSoma is a wellness company dedicated to bringing innovative, effective and high-quality supplement products to the medical, wellness and adult-use markets through our marketing subsidiary, SomaCeuticals™.  SomaCeuticals’s experienced team of industry first movers and enterprising visionaries has acquired a diversified supply of supplements, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market. 

Learn more at and htttps://muscles4u.blogstop.com.  Stay up to date at Twitter: @tweetmuscles4u, Instagram and Facebook

CONTACT

AngioSoma, Inc.

Alex Blankenship

(832) 781- 8521

EN
08/01/2020

Underlying

SOANFIRST TITAN CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIRST TITAN CORP

 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restat...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent Houston, TX, Feb. 11, 2021 (GLOBE NEWSWIRE) --  -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to...

February 11, 2021 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis Houston, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide.   After an intensive search, the Company has identified a well-known firm with a capable team that may be engaged to help with regulatory clearance of the treatment for worldwide treatment of patients. The treatment is encouraged by t...

December 8, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis Houston, TX, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. (a Delaware corporation) for the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis (MS). Multiple Sclerosis (MS) is a chronic disease in which the immune system ...

August 24, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Elects New President

SomaCeuticals Elects New President Houston, TX, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has elected James C. Katzaroff as President to serve until his successor is elected and qualified. Mr. Katzaroff is in discussions with the holder of a patented treatment for Multiple Sclerosis with the intent to negotiate an exclusive perpetual license. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairm...

August 17, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma Focusing on Development of Coating for Metal Stents

AngioSoma Focusing on Development of Coating for Metal Stents Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.  A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into an artery to expand the inside passage and improve blood flow for prevention of vascular restenosis and treatment of complex vascular and coronary disease.  A bifurcated ver...

May 27, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch